

Company name: NeuroSense Therapeutics Website: <https://www.neurosense-tx.com/>
CEO name: Alon Ben-Noon

CATEGORY: Biotech/Pharma Select one SESSION per abstract from the list below
“Beyond Neuropharma and Neurotech: Integrated Brain Control.” Title of the talk: From Idea to Impact: The Scientific Journey of PrimeC Toward Phase 3 in ALS Executive Summary / Investment Rationale NeuroSense Therapeutics is a Nasdaq-listed, clinical-stage biotechnology company advancing PrimeC, a first-in-class, oral, extended-release combination therapy designed to address the multifactorial biology of Amyotrophic Lateral Sclerosis. PrimeC is built on a strong scientific rationale for combination therapy, integrating synergistic mechanisms into a single, synchronized pharmacological intervention. By aligning pharmacokinetics to maximize synergy, PrimeC is designed to concurrently modulate multiple key diseasedriving pathways, including neuroinflammation, iron dysregulation and oxidative stress, and miRNA-mediated regulatory networks. Importantly, this multi-target approach has been clinically demonstrated, with converging biomarker data showing that PrimeC engages several core ALS-relevant biological processes in a coherent and sustained manner in addition to clinical evidence. The ALS market represents a significant and urgent opportunity, characterized by high unmet need and limited disease-modifying therapies. PrimeC has reached Phase 3 readiness following the PARADIGM Phase 2b study, which demonstrated clinically meaningful evidence, including slowing of functional decline and extension of survival, alongside consistent target engagement across key biomarkers. These data support both the therapeutic potential and mechanistic validity of PrimeC’s differentiated approach . From a regulatory and commercial perspective, NeuroSense is advancing a submission strategy in Canada under the Notice of Compliance with Conditions (NOC/c) pathway, positioning PrimeC for potential earlier market access based on promising evidence of clinical effectiveness and a favorable risk-benefit profile. This represents a key near-term value inflection point, alongside preparations for a global Phase 3 program. The company’s strategy focuses on advancing PrimeC toward registration and commercialization, while leveraging its multi-target platform for expansion into additional neurodegenerative indications. Supported by collaborations with leading academic institutions and key opinion leaders, NeuroSense combines deep scientific expertise with strong execution across clinical development, regulatory strategy, and capital markets . Near-term catalysts include Phase 3 initiation and regulatory advancement. Longer-term, NeuroSense aims to establish a leading position in disease-modifying therapies for neurodegeneration, driving value through commercialization, strategic partnerships, and pipeline expansion.